Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: ribociclib, azd-5438, roniciclib +9 | 1.00 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 1 stopped | 0.20 |
| literature PubMed | 11 Parkinson's papers of 3,833 | 0.67 |
| pathways Reactome | 9 pathways; mostly iron and oxidative stress | 0.80 |
No case: the score is under the bar. Receipt 6939
Sealed predictions
- CDK6 in dopamine neurons, braak-0.01 (p 0.982) → +0.21 (p 0.586)receipt 6946
Swarm cases
receipt 6946: CDK6 in dopamine neurons, braak
- power
- full sample +0.13 (p 0.615, n 18), 95% CI -0.36 to +0.56. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.12 (p 0.627, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.12 (p 0.646, n 18). could be the mix.
- skeptic
- leave-one-out range +0.01 to +0.24, sign flips 0; without severely affected donors +0.13 (p 0.615, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CDK6 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts